Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

Revital-maker Sun Pharma receives USFDA warning over violations at Halol facility

The letter specifies violations at its Halol facility, with regards to manufacturing of goods.

FPJ Web DeskUpdated: Friday, December 16, 2022, 07:35 PM IST
article-image
Representational image |

Through an exchange filing, Revital maker Sun Pharma has informed that it has received a warning letter from the US Food and Drug Administration.

The letter specifies violations at its Halol facility, with regards to manufacturing of goods, and contents of the letter will be released to the public soon.

RECENT STORIES

RBI Withdraws ₹1 Lakh Crore Via 7-Day VRRR Auction To Curb Surplus Banking Liquidity Levels

RBI Withdraws ₹1 Lakh Crore Via 7-Day VRRR Auction To Curb Surplus Banking Liquidity Levels

BSE Schedules Mock Trading For Equity Segment, Members Invited To Test Systems On July 5

BSE Schedules Mock Trading For Equity Segment, Members Invited To Test Systems On July 5

IRB InvIT Fund Unitholders Approve Acquisition Of 100% Equity Share Capital Of Three Special Purpose...

IRB InvIT Fund Unitholders Approve Acquisition Of 100% Equity Share Capital Of Three Special Purpose...

RBI Brings Big Relief For Borrowers, No Charges On Early Loan Repayment From January 2026

RBI Brings Big Relief For Borrowers, No Charges On Early Loan Repayment From January 2026

US-India Trade: Pact To Be Finalised Before July 9,Issues With Agriculture & Auto Sectors To Be...

US-India Trade: Pact To Be Finalised Before July 9,Issues With Agriculture & Auto Sectors To Be...